Beta Bionics Inc

BBNX remains in a Stage 2 uptrend with successive higher highs and higher lows above rising EMAs. The medium-term bias is bullish, but short-term price is extended above EMAs and in extreme overbought RSI territory, warranting patience. Preferred entries are on pullbacks into the 9- and 20-day EMA support zone for continuation participation.

• ↑Net sales grew 38% YoY to $32M in Q2 2026, led by new patient starts
• ↑Pharmacy channel now reimburses ~37–39% of patient starts, lowering costs
• ↓Operating expenses jumped 37% YoY to $44.5M, pressuring profitability